Pfizer (NYSE:PFE) Releases FY21 Earnings Guidance

Share on StockTwits

Pfizer (NYSE:PFE) issued an update on its FY21 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.97. Pfizer also updated its FY 2021
After-Hours guidance to 3.00-3.10 EPS.

PFE opened at $36.86 on Thursday. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. Pfizer has a 52 week low of $27.88 and a 52 week high of $43.08. The business’s 50 day moving average is $38.25 and its two-hundred day moving average is $37.19. The firm has a market cap of $204.88 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business had revenue of $12.13 billion for the quarter, compared to analyst estimates of $12.30 billion. During the same period last year, the firm posted $0.75 earnings per share. The company’s revenue for the quarter was down 4.3% compared to the same quarter last year. Equities analysts expect that Pfizer will post 2.84 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 5th. Shareholders of record on Friday, January 29th will be paid a $0.39 dividend. The ex-dividend date is Thursday, January 28th. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a yield of 4.23%. Pfizer’s payout ratio is currently 51.53%.

A number of equities analysts recently issued reports on the company. Zacks Investment Research raised Pfizer from a sell rating to a hold rating and set a $37.00 price target on the stock in a report on Thursday, October 29th. BidaskClub downgraded Pfizer from a sell rating to a strong sell rating in a research note on Thursday, December 31st. Barclays upped their price target on Pfizer from $35.00 to $37.00 and gave the stock an equal weight rating in a research note on Friday, December 4th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Tuesday, November 10th. They issued a market perform rating and a $42.00 price objective on the stock. Finally, SVB Leerink upped their price objective on shares of Pfizer from $42.00 to $43.00 and gave the stock a market perform rating in a research report on Wednesday, October 28th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $39.87.

In other news, major shareholder Pfizer Inc acquired 1,200,000 shares of Pfizer stock in a transaction that occurred on Tuesday, October 27th. The stock was purchased at an average cost of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the acquisition, the insider now owns 27,349,211 shares in the company, valued at approximately $273,492,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.08% of the company’s stock.

About Pfizer

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Featured Story: Backdoor Roth IRA Conversion and Strategy

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.